Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
David Henry MD
David Henry MD Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · August 26, 2022

Olaparib Maintenance Therapy in Patients With Chemosensitive SCLC

Lung Cancer

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

Lung Cancer
Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial
Lung Cancer 2022 Jul 15;171(2022)26-33, P Woll, P Gaunt, S Danson, N Steele, S Ahmed, C Mulatero, R Shah, J Bhosle, E Hodgkinson, B Watkins, L Billingham

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated